Temporin-PE - Tat (48–57)

General Information


DRACP ID  DRACP00807

Peptide Name   Temporin-PE - Tat (48–57)

Sequence  FLPIVAKLLSGLLGRKKRRQRRR

Sequence Length  23

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
NCI-H157 Lung squamous cell carcinoma Carcinoma IC50=3.464µM MTT assay 24h 1
U-251MG Astrocytoma Carcinoma IC50=3.087µM MTT assay 24h 1
PC-3 Prostate carcinoma Carcinoma IC50=3.051µM MTT assay 24h 1
MDA-MB-435S Amelanotic melanoma Carcinoma IC50=3.483µM MTT assay 24h 1

Hemolytic Activity  Horse erythrocytes: 50% Hemolysis=44.65µM

Normal (non-cancerous) Cytotoxicity  HMEC-1: IC50=9.976µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00807

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C124H225N45O26

Absent amino acids  CDEHMNTWY

Common amino acids  R

Mass  315502

Pl  13.21

Basic residues  9

Acidic residues  0

Hydrophobic residues  9

Net charge  9

Boman Index  -7488

Hydrophobicity  -56.96

Aliphatic Index  118.7

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 29191658

Title  Identification and target-modifications of temporin-PE: A novel antimicrobial peptide in the defensive skin secretions of the edible frog, Pelophylax kl. Esculentus

Doi 10.1016/j.bbrc.2017.11.173

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.